BizCommunity 8 Feb 2022
"US federal regulators pressed Pfizer and BioNTech to submit a request for emergency authorisation of the Covid-19 vaccine from the United States Food and Drug Administration for children six months to five years old.
This is even though it's been reported two doses failed to produce the hoped-for immune response among children aged two to four in a clinical trial.
This would mean that children under the age of five in the USA could soon be receiving their Covid-19 vaccinations.
After approval, a vaccine dose will contain 10% of the active ingredient that people from the age of 12 get.
Pfizer-BioNTech said they now continue to review the third dose in clinical trials while commencing the FDA process."
Read more:
